![](/media/news-and-events/publiclectures/21-22/psilocybin.jpg)
Will psilocybin lose its magic in the clinical setting? Dr Caroline Hayes, NHS
Event details
Drug Science Society Lecture
Psilocybin as a novel treatment for depression is garnering a lot of attention from both the mainstream media and the academic community, however, there are a number of potential pitfalls that will need to be addressed if Psilocybin is to become a licensed treatment for depression. This talk will look at a patient case study from the recent phase IIb Compass Pathways trial looking at Psilocybin for treatment-resistant depression that ran in Newcastle, and consider a number of ethical issues in psychedelic research.
Dr Caroline Hayes is a doctor working in the NHS on the core psychiatry training programme. She was a sub-investigator on the phase IIb Psilocybin for treatment resistant depression trial run by Compass Pathways, however, no longer participates in psychedelic research due to ethical concerns.
Partners
![York Drug Science Society](/media/news-and-events/publiclectures/23-24/York Drug Science Society.png)